---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041320"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:45:10.075129+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma Q2 net loss $29.6M ($0.78/sh); cash $196.3M; LIFT-AD results H2 2024

## Summary
- Net loss $29.6M ($0.78/sh) vs $24.3M ($0.65/sh) in Q2 2022; R&D spend rose to $21.6M.
- Cash, cash equivalents and investments $196.3M at June 30, 2023, down from $245.2M at Dec 31, 2022.
- Completed end-of-Phase 2 FDA meeting for fosgonimeton; LIFT-AD topline expected H2 2024.
- Appointed Andrew Gengos as CFO and Chief Business Officer.
- IND-enabling studies for ATH-1105 continue; first-in-human studies targeted H1 2024 for ALS.

## SEC filing metadata
- accession: 0000950170-23-041320
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017023041320/0000950170-23-041320-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017023041320/atha-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041320
- JSON: https://secwatch.observer/filing/0000950170-23-041320.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041320.txt

## Key facts
- Earnings Releases
  LeonaBio, Inc. reported financial results for quarter ended June 30, 2023.
  - Period: quarter ended June 30, 2023
  - Result: reported results
  source text: On August 10, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1620463/000095017023041320/0000950170-23-041320-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.